KLH conjugation of ssDNA/dsDNA, RNA, and cDNA with matched BSA/OVA screening antigens for anti-DNA antibody (“oligobody”) generation5 and assay development. IgG and CPP options available. Controlled loading, chemistry selection, purification, and QC.
Bio‑Synthesis provides a specialized KLH oligonucleotide conjugation service and broader nucleic acid–carrier protein conjugation platform for immunogen and assay applications. We conjugate single‑ and double‑stranded DNA, RNA, and cDNA constructs to validated carrier systems to support anti‑DNA antibody generation (“oligobody”), anti‑RNA antibody programs, and bioanalytical method development. With over 30 years of nucleic acid chemistry and bioconjugation experience, our builds are designed around controlled epitope presentation, defined oligo‑to‑carrier loading ranges, purification to remove free oligo, and analytical confirmation. Our core, high‑volume workflow centers on KLH immunogens paired with matched BSA screening conjugates1,3 (with optional OVA confirmatory screening) to reduce anti‑carrier bias and confirm sequence‑specific binding.
High‑throughput, routine builds. Primary immunization constructs for anti‑DNA/RNA and anti‑ASO/siRNA antibody generation.
BSA is a core platform for screening and assay antigens; OVA is commonly used as an orthogonal confirmatory carrier to reduce background.
Hybrid constructs for detection platforms or uptake studies when function (not immunogenicity) is the goal.
ssDNA • ssRNA • dsDNA • dsRNA • ASO • SSO • siRNA duplex • PNA • PMO • and modified backbones (PS, 2′-OMe, 2′-F, LNA, etc.). Single- and double-stranded constructs are supported, including strand-selective strategies for duplex formats.
A common best-practice approach is KLH–oligo for immunization and BSA–oligo or OVA–oligo for screening ELISA. This pairing reduces anti-carrier bias and confirms oligo-specific binding.
If you routinely immunize with KLH, we can provide matched BSA screening conjugates (same oligo sequence/handle strategy) to accelerate ELISA setup and reduce anti‑carrier background in early screening.
We select conjugation chemistry based on the carrier (KLH/BSA/OVA/IgG/CPP), strand format (ss vs ds), available handles (amine/thiol/azide/alkyne), and the degree of control required over loading and orientation. Below are common approaches for immunogen and assay conjugates; the method is chosen to balance robustness, heterogeneity tolerance, and immunization or assay performance.
Widely used for KLH/BSA/OVA. Fast and robust, but produces broader loading distributions; manage via target loading ranges and purification.
Improved control versus random lysine coupling; often preferred for IgG or when limiting over‑modification is important.
Two‑step workflow that supports consistent builds and better control of orientation versus one‑step random coupling.
Useful for selected assay constructs; apply conservatively to avoid unintended carrier modification that can impact performance.
High specificity with minimal off‑target modification; preferred when tight control over loading/orientation is required (e.g., IgG, CPP, duplex formats).
Used for uptake/functional studies rather than immunization; define stoichiometry and confirm construct integrity.
Carrier (KLH/BSA/OVA/IgG/CPP) • strand format (ss vs ds) • handle chemistry • target loading range • screening plan (BSA/OVA pairing) • heterogeneity tolerance.
We support double-stranded DNA and double-stranded RNA (including siRNA duplexes). Duplex formats require additional planning for strand selectivity and integrity.
Maintain ds integrity while tightening heterogeneity: distinguish free oligo, free carrier, and conjugate species; confirm integrity post-conjugation using an appropriate analytical strategy.
Removing free oligo improves dosing accuracy in immunization and reduces confounding signals in assay workflows. It also improves interpretability when comparing carriers (KLH vs BSA vs OVA) across an antibody generation program.
KLH immunogens to raise antibodies against defined sequences or modified oligo chemistries.
Antibodies for bioanalytical and immunogenicity workflows across ASO and siRNA programs.
BSA/OVA conjugates for screening and confirmatory assays to reduce anti-carrier background.
Carrier-linked constructs for method development, specificity controls, and assay calibration.
CPP conjugates for cellular uptake evaluation and intracellular activity studies (program-dependent).
IgG–oligo constructs for detection or scaffolded assay systems with loading control.
To speed technical review of a KLH oligonucleotide conjugation program, please provide:
In addition to carrier protein immunogen conjugates (KLH, BSA, OVA, IgG, CPP), we also support alternative oligonucleotide conjugation platforms when different presentation, delivery, or structural strategies are required.
Lipid-based systems for membrane interaction, encapsulation strategies, or delivery-oriented research workflows. Suitable when cellular uptake or biodistribution behavior is the primary objective.
Conjugation to synthetic scaffolds including dextran, agarose, and poly-L-lysine for multivalent display, immobilization, or assay platform development.
Branched dendritic architectures enabling high-density oligonucleotide presentation, structural organization, or specialized research constructs requiring controlled multivalency.
These options are typically selected when multivalent display, delivery behavior, or immobilization is central to your experimental design (rather than antibody generation).
A covalent construct that links ssDNA/ssRNA or dsDNA/dsRNA to a carrier platform (KLH, BSA, OVA, IgG, or CPP) for immunization, antibody production, assay development, or functional uptake studies.
A common workflow is KLH–oligo for immunization and BSA–oligo or OVA–oligo for screening ELISA. This reduces anti-carrier background and confirms oligo-specific binding.
Yes. We support dsDNA and dsRNA (including siRNA duplexes) using strand-selective or duplex-preserving approaches, with integrity checks after conjugation.
Chemistry influences loading distribution, epitope orientation, carrier integrity, and residual free oligo. These factors affect antigen presentation, anti-carrier bias, and the specificity and titer of the antibody response.
Yes. We can conjugate modified oligos including PS and common 2′ sugar chemistries. Provide the modification pattern and target region for recognition so the attachment site can be selected appropriately.
Typical confirmation includes SDS-PAGE (carrier-dependent), UV/Vis ratioing, and optional SEC-HPLC. Analytical scope is aligned to the program goal (immunization vs assay performance vs functional uptake studies).
Share your oligo format (ss or ds), carrier preference (KLH/BSA/OVA/IgG/CPP), and your immunization or assay plan. We’ll recommend conjugation chemistry, a target loading range, purification strategy, and an analytical confirmation plan.
For new programs, consider two builds: (1) a robust baseline method (e.g., SMCC-type or NHS ester), and (2) a higher-control method (thiol or click). Compare by loading, free oligo, and ELISA performance (BSA/OVA screening), then standardize the best-performing route.
Selected resources on oligonucleotide delivery and ligand-directed uptake concepts.
Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.